AU2001294515A1 - Use of stat-6 inhibitors as therapeutic agents - Google Patents

Use of stat-6 inhibitors as therapeutic agents

Info

Publication number
AU2001294515A1
AU2001294515A1 AU2001294515A AU9451501A AU2001294515A1 AU 2001294515 A1 AU2001294515 A1 AU 2001294515A1 AU 2001294515 A AU2001294515 A AU 2001294515A AU 9451501 A AU9451501 A AU 9451501A AU 2001294515 A1 AU2001294515 A1 AU 2001294515A1
Authority
AU
Australia
Prior art keywords
stat
inhibitors
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294515A
Inventor
Sylvie Barchechath
Dennis A. Carson
Howard B Cottam
Lorenzo M. Leoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/637,531 external-priority patent/US6696441B1/en
Application filed by University of California filed Critical University of California
Publication of AU2001294515A1 publication Critical patent/AU2001294515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001294515A 2000-08-11 2001-08-10 Use of stat-6 inhibitors as therapeutic agents Abandoned AU2001294515A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/637,531 US6696441B1 (en) 2000-08-11 2000-08-11 Inhibition of p53-induced stress response
US09/637,531 2000-08-11
US30134001P 2001-06-26 2001-06-26
US60/301,340 2001-06-26
PCT/US2001/025175 WO2002014321A1 (en) 2000-08-11 2001-08-10 Use of stat-6 inhibitors as therapeutic agents

Publications (1)

Publication Number Publication Date
AU2001294515A1 true AU2001294515A1 (en) 2002-02-25

Family

ID=26972310

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294515A Abandoned AU2001294515A1 (en) 2000-08-11 2001-08-10 Use of stat-6 inhibitors as therapeutic agents

Country Status (2)

Country Link
AU (1) AU2001294515A1 (en)
WO (1) WO2002014321A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861431B2 (en) 2001-03-23 2005-03-01 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
FR2910895B1 (en) * 2006-12-29 2010-08-27 Biopharmed "IMINO-TETRAHYDROBENZOTRIAZOLES DERIVATIVES HAVING ANTI-MIGRATORY PROPERTIES OF DEPENDENT METASTASES"
WO2008155441A1 (en) * 2007-06-20 2008-12-24 Marikki Laiho Activators and therapeutic applications thereof
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
EP2218464A1 (en) * 2009-02-11 2010-08-18 Technische Universität München Compounds for non-invasive measurement of aggregates of amyloid peptides
US8569002B2 (en) 2010-10-20 2013-10-29 The Board Of Regents Of The University Of Texas System Multiplexed luciferase reporter assay systems
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
TWI648282B (en) 2014-03-27 2019-01-21 印度商托仁特生技有限公司 New fusion imidazole benzothiazole compound
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3394033T3 (en) 2015-12-22 2021-01-04 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNE MODULATORS
MA44860A (en) 2016-05-06 2019-03-13 Incyte Holdings Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018076534A2 (en) 2016-06-20 2019-04-02 Incyte Corporation heterocyclic compounds as immunomodulators
ES2930092T3 (en) 2016-07-14 2022-12-07 Incyte Corp Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MA47120A (en) 2016-12-22 2021-04-28 Incyte Corp PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS
CR20200520A (en) 2018-03-30 2021-03-09 Incyte Corp Heterocyclic compounds as immunomodulators
EP3790877B1 (en) 2018-05-11 2023-03-01 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
TW202115059A (en) 2019-08-09 2021-04-16 美商英塞特公司 Salts of a pd-1/pd-l1 inhibitor
TW202126652A (en) 2019-09-30 2021-07-16 美商英塞特公司 Pyrido[3,2-d]pyrimidine compounds as immunomodulators
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CA3200844A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
JPH11106340A (en) * 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Stat6 activation inhibitor
DE60037394T2 (en) * 1999-01-29 2009-01-02 The Board Of Trustees For The University Of Illinois, Urbana USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS IN CANCER THERAPY

Also Published As

Publication number Publication date
WO2002014321A9 (en) 2003-03-27
WO2002014321A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU2001294515A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
GB0025782D0 (en) Use of inhibitors
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2002322719A1 (en) Delivery of therapeutic capable agents
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
AU2003261251A1 (en) Methods of delivering therapeutic agents
IL149106A0 (en) Therapeutic use of selective pde10 inhibitors
GB0010183D0 (en) Inhibitors of dipeptidyl peptidase IV
HUP0300061A3 (en) Use of il-18 inhibitors
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU8969601A (en) New use of lipase inhibitors
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU1929301A (en) Methods of use of peptide deformylase inhibitors as novel antibacterial agents
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
IL131047A0 (en) Use of il-18 inhibitors
AU2001274344A1 (en) Tissue inhibitors of matrix metalloproteinases
IL160230A0 (en) Use of il-18 inhibitors
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU1212002A (en) Use of lipase inhibitors
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU2002305868A1 (en) Inhibitors of reggamma
AU2001283964A1 (en) Composition for combined use of aromatase inhibitors